Recent Comments

Comment RSS

Search results for 'Anastrozole'


New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well. http://www.news-medical.net/news/20091211/New-data-suggests-bisphosphonate-drug-may-play-a-role-in-reducing-recurrent-breast-cancer.aspx
Postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 gene deficiency Findings from a new study have prompted Mayo Clinic researchers to recommend CYP2D6 gene testing for postmenopausal women about to begin tamoxifen therapy. http://www.news-medical.net/news/2008/12/14/44176.aspx
Side effects predict succes of breast cancer treatment Hot flushes, night sweats and painful joints can be a blessing in disguise for breast cancer patients - according to a new report published online in the Lancet Oncology. http://www.news-medical.net/news/2008/11/02/42289.aspx
No link between aromatase inhibitors and cardiovascular problems New evidence has emerged that, contrary to some current fears, aromatase inhibitors (AIs) are not associated with an increased risk of heart problems in women who take them to prevent their breast cancer recurring. http://www.news-medical.net/news/2008/04/17/37439.aspx
Study looks at denosumab in preventing bone loss caused by aromatase inhibitors Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. http://www.news-medical.net/news/2007/12/17/33597.aspx
Early results show promise in reducing side effects from anastrozole A common osteoporosis drug can shield women against the loss of bone mineral density - a side effect of the drug anastrozole which is taken to prevent breast cancer in the IBIS-2 study - according to new data presented at the San Antonio Breast Cancer Symposium. http://www.news-medical.net/news/2007/12/14/33531.aspx
AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (anastrozole) AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010. http://www.news-medical.net/news/2007/12/02/33071.aspx
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study. http://www.news-medical.net/news/2007/02/12/21825.aspx
Combination of anastrozole and a synthetic hormone called goserelin may slow male breast cancer growth Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage. http://www.news-medical.net/news/2006/07/10/18764.aspx
Warning of risk of from vaginal oestrogen Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane. http://www.news-medical.net/news/2006/01/26/15644.aspx
Aromatase inhibitors may slow growth of lung cancer A few years ago researchers discovered that, much like breast tumors, some lung tumors also thrive on estrogen. Now a medical student conducting research on a Howard Hughes Medical Institute (HHMI) fellowship and colleagues have managed to stop the growth of human lung cancer cells in mice with a class of breast cancer drugs called aromatase inhibitors. http://www.news-medical.net/news/2005/12/15/15014.aspx
NHS under pressure to provide new breast cancer drugs The National Health Service in the UK is being put under considerable pressure by Cancer charities to widen access to a promising new class of breast cancer drug as new evidence suggests the latest treatment is far superior to Tamoxifen, the long established premier drug for women with the early stage of the disease. http://www.news-medical.net/news/2005/12/12/14953.aspx
AstraZeneca receives the coveted Frost & Sullivan award Acknowledging AstraZeneca's hugely successful hormonal breast cancer therapy, anastrozole (Arimidex), Frost & Sullivan presented the company with the prestigious 2005 Pharmaceutical Industry Product of the Year Award. http://www.news-medical.net/news/2005/09/20/13180.aspx
Switching treatment to the drug anastrozole after two years of tamoxifen is beneficial for women with early breast cancer Switching treatment to the drug anastrozole after two years of tamoxifen can improve eventfree survival for postmenopausal women with early breast cancer, concludes a study in this week’s issue of The Lancet. http://www.news-medical.net/news/2005/08/04/12297.aspx
Women in the UK most anxious about breast cancer A new survey has found that one in three British women would be willing to have both breasts removed if they thought they were at high risk of breast cancer. http://www.news-medical.net/news/2005/06/13/10944.aspx
New drug combination prevents breast cancer growth pre-surgery A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs. http://www.news-medical.net/news/2005/05/17/10132.aspx
Gefitinib (Iressa) could reduce the size of breast cancer tumours Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology. http://www.news-medical.net/news/2005/05/17/10129.aspx
Call for Anastrozole (Arimidex) to be the new preferred breast cancer treatment option An international group of breast cancer experts called for the aromatase inhibitor (AI), anastrozole ('Arimidex'), to be considered as the new 'preferred treatment option' for postmenopausal women with early breast cancer. http://www.news-medical.net/news/2005/01/24/7453.aspx
Landmark studies that may change the treatment standards for breast cancer The 27th Annual San Antonio Breast Cancer Symposium that took place December 8-11 included the presentation of several landmark studies that may change the treatment standards for breast cancer. http://www.news-medical.net/news/2004/12/14/6858.aspx
More women are surviving advanced breast cancer Writing in the Journal of Clinical Oncology, (Vol. 22, No. 16: 3302-3308), doctors from 3 French hospitals reported on 724 women whose first diagnosis was breast cancer that had spread to other parts of the body (stage 4). It is rare for women to be diagnosed with such late stage disease. http://www.news-medical.net/news/2004/08/27/4373.aspx
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.